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ABSTRACT 
Chronic liver disease is a major cause of morbidity and mortality worldwide marked by 
chronic inflammation and fibrosis/scarring, resulting in end-stage liver disease and its 
complications. Hepatic stellate cells (HSCs) are a dominant contributor to liver fibrosis by 
producing excessive extracellular matrix (ECM), irrespective of the underlying disease 
aetiologies, and for many decades research has focused on the development of a number of 
anti-fibrotic strategies targeting this cell. Despite major improvements in two-dimensional 
systems (2D) by using a variety of cell culture models of different complexity, an efficient 
anti-fibrogenic therapy has yet to be developed. The development of well-defined three-
dimensional (3D) in vitro models, which mimic ECM structures as found in vivo, have 
demonstrated the importance of cell-matrix bio-mechanics, the complex interactions between 
HSCs and hepatocytes and other non-parenchymal cells, and this to improve and promote 
liver cell-specific functions. Henceforth, refinement of these 3D in vitro models, which 
reproduce the liver microenvironment, will lead to new objectives and to a possible new era 
in the search for antifibrogenic compounds.  
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1. Introduction 
1.1. The liver and pathophysiology 
The liver metabolises drugs, detoxifies chemicals and produces vital molecules such as 
blood-clotting proteins and bile, stores energy by accumulating glycogen, and protects the 
body by neutralizing foreign antigens and microbes from the gut. In order to maintain 
homeostasis in the organism the liver filters the blood arriving from the digestive tract before 
it is delivered to the rest of the body. As a secondary lymphoid organ, the liver plays an 
important role in the immune system and produces acute phase and serum proteins [1]. 
Alongside the hepatocytes being the parenchymal cells [2], the liver contains non-
parenchymal cells (NPCs) such as Liver Sinusoidal Endothelial Cells (LSECs) [3], Hepatic 
Stellate Cells (HSCs) [4], Kupffer cells [5], Natural Killer cells [6] and different types of 
immune cells [7, 8]. Each different NPC participates to the liver function and hepatotoxic 
mechanisms by performing important secondary responses upon hepatocyte damage [9].  
Liver fibrosis results from chronic liver injury of different aetiologies. In Western countries, 
Hepatitis C Virus (HCV) infection, Hepatitis B Virus (HBV) infection, certain metabolic 
liver diseases, hereditary hemochromatosis, porphyria and heavy alcohol intake as well as 
nonalcoholic fatty liver disease (NAFLD) and its more aggressive form nonalcoholic 
steatophepatitis (NASH) are all liver diseases which if not treated, lead to chronic injury. 
Indeed, indifferent from aetiology/cause, and if left untreated will prime the development of 
liver fibrosis and subsequently cirrhosis [10]. Hence, fibrosis is considered to be a 
deregulated repair response i.e. woundhealing, characterized by hepatocyte necrosis, 
inflammation, oxidative stress and excessive ECM deposition which may culminate in 
cirrhosis. These conditions of end stage liver cirrhosis promotes the perfect 
microenvironment to develop primary liver cancer i.e. hepatocellular carcinoma (HCC). In 
fact almost all cases of primary liver cancer are marked by the presence of cirrhosis [11].  
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1.2. Hepatic stellate cells, ECM producing cells 
In a healthy liver the ECM of the normal perisinusoidal space is made up by a well-balanced 
and specific quantitative and qualitative amount of collagen type I, III, IV, V and VI, 
fibronectin, laminin and proteoglycans which has been proven to perform a critical role in 
maintaining the in vivo phenotype of both hepatocytes and NPCs [12-14]. Hepatic stellate 
cells are located in the perisinusoidal space of Disse, HSCs adhere to the endothelial cells and 
make contact with the hepatocytes [4, 15, 16]. Upon liver injury, and especially during 
chronic liver damage, a dynamic and programmed event occur in which HSCs 
“transdifferentiate” and become activated by a paracrine stimulation followed by autocrine 
amplification of the fibrogenic signals [15, 17]. These events result in a complex and 
bidirectional signalling network between different cell types and their mediators leading to 
the accumulation of ECM proteins and hepatic fibrosis [18, 19]. Moreover, fibrogenic hepatic 
myofibroblasts predominantly arise from liver resident HSCs [20, 21], thus a major player in 
ECM modification during acute and chronic liver injury are activated HSCs. Rather than an 
uncontrolled, continuous process of ECM secretion and deposition, hepatic fibrosis is 
characterized by a shift in the balance between deposition and degradation due to changes in 
matrix metalloproteinases (MMPs) and their inhibitors i.e. the tissue inhibitor of MMPs 
(TIMPs) [12, 22-24]. Therefore, already activated by the initial stimulus, HSCs express and 
secrete higher levels of fibrillar collagens type I, II and III, thus forming thick and highly 
cross-linked collagen bundles. As a result, this interrupts the normal fine balance from a 
collagen type IV laminin-rich low-density basement membrane-like structure into a 
remodelled collagen type I and III-rich fibrillar matrix [25-29]. These changes in collagen 
production can become so dramatic that the total content of collagens and the non-
collagenous components increases 3- to 5-fold, indicating that the 3 dimensional (3D) 
network formed by the ECM in the space of Disse is a very dynamic phenomenon [14]. 
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Furthermore, these changes in hepatic ECM are correlated with specific ECM serum 
concentrations [29-31].  
In the past decades, several approaches to isolate HSCs have been used that include; density 
gradient separation, fluorescent cell sorting and explant culture [4]. The method to separate 
HSCs from other hepatic cells is based on employing an ex-vivo enzymatic digestion of the 
liver tissue by collagenases, pronases and DNase allowing for the dissociation of the hepatic 
cells from the surrounding ECM [32-34]. This can be followed by several centrifugation steps 
and a refined multistep or single step gradient centrifugation or flow cytometry/FACS 
analysis. Freshly isolated HSCs are presented with prominent dendritic cytoplasmic processes 
and retinoids containing lipid droplets. The cells will gradually display a slightly more 
myofibroblast phenotype marked by heterogeneous retinoid droplet size during the following 
days in culture [4, 35, 36]. Henceforth over several decades, many in vitro investigations 
have demonstrated the remarkable cell plasticity of HSCs that not only reflects various 
phenotypes but also mirrors different functions. 
2. HSCs on 2D culture systems  
In general, over the last 5 decades the most described and used model to investigate cell 
biology/behaviour is the traditional 2D monolayer culture where investigators culture the 
cells on stiff and flat polystyrene dishes. Additionally, in the field of liver cell biology, 
investigators have used this model to explore HSCs biology. By using non-coated plastic 
cultures in the presence of foetal bovine serum, observations were made that when culturing 
primary quiescent HSCs, obtained from a healthy liver, cells spontaneously 
“transdifferentiate” into an activated myofibroblast-like cell, characteristic of a diseased liver. 
Therefore, this system represented for many years an in vitro culture model to compare 
quiescent healthy cells versus activated cells present in the diseased liver.  
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The definition of the HSCs “activation” refers to the conversion of a resting vitamin A-rich 
cell into a cell type which was characterized by proliferation, fibrogenesis and being highly 
contractile as was observed in 2D flat un-coated polystyrene dishes [14, 37]. This single 
mono culture of quiescent HSCs has demonstrated alterations in important proteins and genes 
during HSCs activation in vitro. Moreover, drug treatment of culture-activated HSCs showed 
to inhibit or to reverse this activated HSCs phenotype by inhibiting ECM de novo synthesis, 
proliferation and contraction [38-41]. Limitations in this experimental set-up and differences 
between in vitro culture activation and in vivo activation were first demonstrated by 
comparing activated HSCs isolated from fibrosis-induced rodents injected with carbon 
tetrachloride (CCl4) or treated with Vitamin A [26, 42]. Indeed, significant differences were 
demonstrated in HSCs lipid droplets accumulation, proliferation rate, and very important, 
alterations in the ratio of collagen type I to type III produced by HSCs from CCl4 was 
enhanced as compared with control rats. In addition, HSCs proliferation strongly increased 
when cells were co-cultured with Kupffer cells isolated from CCl4 treated animals in 
comparison to Kupffer cells isolated from control animals [26, 42]. Differences were 
observed between HSCs phenotypes i.e. in vitro culture activated HSCs versus in vivo 
activated HSCs obtained from CCl4 and BDL induced activated HSCs. Deminics et al., 
employed mouse microarray analysis and demonstrated that various genes were differently 
affected depending on the model used such as genes involved in proliferation (Ki 67), cell 
survival (survivin, septin 4), cytoskeletal organization and contraction (plexin C1, anillin, 
leiomodin), inflammation (CXCL14, osteopontin), ECM organization and degradation 
(Col8a1, MMP10), and lipid metabolism (cholesterol 25-hydroxylase) as well as transcription 
factors (PRX1, LMCD1), cell surface receptors (adenosine receptor 2b, GPR91), bone 
morphogenetic protein BMP5, and neural markers (synaptotagmin, neurotrimin) [35, 43, 44]. 
Furthermore, gene expression microarray analysis and proteomics showed a clear difference 
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between in vitro-activated and in vivo-activated HSCs. In addition, data showed that when 
cells were isolated at various time points after cessation of injury i.e. after recovery, cells 
were characterized by diminished expression of activated HSCs markers, but stayed primed 
[35, 45-47]. Overall, these data indicate that the in vivo-activated HSCs may reflect more the 
influence of the specific microenvironment on their behaviour in the fibrotic liver which 
favour the use of in vivo-activated HSCs isolated from a fibrotic liver over in vitro culture 
activated HSCs isolated from a healthy liver when exploring new antifibrotic targets and 
drugs.  
 
2.1.  HSCs interacts with different hepatic cells.  
 
Co-culture systems have been used to explore the intercellular communication between HSCs 
and other hepatic cells. Liver fibrogenesis is sustained and modulated by an intense cross-talk 
between different hepatic cell populations that involves the synthesis and release of several 
mediators, including growth factors, cytokines, chemokines, reactive oxygen species, 
adipokines, vasoactive agents and plasma proteins. Cell-cell interactions have been 
investigated by co-culturing cells in direct contact with one and another to measure overall 
changes in gene/protein expression as well as functional changes for example induction in 
proliferation and migration. Indeed, many experiments in 2D culture systems have shown a 
clear interaction i.e. cross-talk between HSC and Kupffer [48], hepatocytes [49], liver 
sinusoidal endothelial cells (LSEC) [3] cholangiocytes [50] and HCC [51] as well as with 
platelets [52], and with cells of the immune system [53-55]. This approach does not 
discriminate between the effects of one cell type vs the other cell type, but identifies the 
overall effect of growing the cells together. Only in the context of non-adherent immune cells 
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in co-culture with HSCs one can wash away the immune cells after incubation and measure 
specific functional and specific changes in gene/protein expression of HSCs. Indirect co–
cultures can be established by using transwell inserts, to separate both cell types, but permits 
access of secreted factors to affect genes or proteins in both cell types of interest. To obtain a 
clear readout of how one cell type can affect the cell behaviour of HSCs one can measure the 
direct paracrine effect by culturing the HSCs with the conditioned medium of the other cell 
type. This conditioned medium contains all cytokines, growth factors/soluble factors, 
exosomes, microparticles and lysosomes produced and secreted by the hepatic cell [42, 56-
58]. Furthermore, activated HSCs secrete cytokines and growth factors that can stimulate the 
growth, proliferation, and migration of cancer cells, as well as other non-neoplastic cells 
within the liver tumour stroma. This was demonstrated by exposing cancer cells to the 
conditioned medium collected from activated HSCs and vice versa [51, 59-62]. Investigating 
the content of the conditioned medium will identify possible key players/mechanisms and 
their functions during the cross talk between HSCs and other hepatic cells [44].  
 
2.2.  Single cell culture and 2D: importance of adhesion, RGD and matrix components 
 
Many studies have demonstrated the involvement of important signalling pathways in cellular 
adhesion processes which also differ when HSCs are grown on plastic, collagen or cultured 
on ECM [63-65]. These obtained advances to control the ECM composition have facilitated 
those studies that explain the spatial distribution of integrin-mediated adhesion, cellular 
function, polarity and proliferation [66]. Several ECM proteins activate integrins through 
different mechanisms, resulting in the integration of multiple signalling pathways and thus 
different cellular behaviours. In fact, cells assume a specific morphology based on integrin-
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mediated adhesions to the extracellular matrix, this is observed when comparing cells on a 
flat surface, where adhesion occurs on one plane of the cell, to those cultured in a 3D 
microenvironment, where adhesion occurs on all planes (Figure 1).  
Moreover, Chen et al., have discovered a new role for integrins in mediating HSCs-derived 
exosomes, in which these exosomes bind to neighbouring HSCs which in turn alters the pro-
fibrogenic exosome-regulated functions in these HSCs [67]. From the chemical point of view, 
ECM proteins containing an Arg–Gly–Asp (RGD) sequence are known to alter cell functions. 
Indeed, the most basic biological functionality in using 2D cultures in combination with ECM 
is achieved by addition of cell-adhesive ligands, commonly used RGD peptides. For example, 
fibronectin is an ECM protein with this specific peptide sequence, RGD that alters cellular 
attachment and spreading, as well as cell integration properties [68]. Until today, the RGD 
peptide is a major adhesive domain of several ECM components, such as that involved in the 
binding of fibronectin [69], an important assembler of the collagen matrix to the alpha5beta1 
integrin receptor [70] with the presence of intra-molecular RGD motif in collagen [71].  
2.3.  HSCs mechanotransduction and biomechanics 
As mentioned before, several in-depth studies have shown that during the process of chronic 
liver disease, changes in specific protein families of the ECM such as collagens, laminins and 
integrins give rise to the formation of new and specific networks with their specific ligands 
and receptors. For example, collagen is the most abundant component of scaffolding ECM in 
tissue stroma and is essential for the macromolecular structure [72]. Moreover, collagen-
mediated ECM networks have a strong effect on biological properties such as matrix/tissue 
stiffness and therefore tissue/organ structure. These events add up to the complexity of the 
ECM microenvironment that forms a support for the intrinsic communication between cells 
as well as functioning as a reservoir for the secreted growth factors, cytokines, exosomes and 
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matricellular proteins during liver injury. This further indicates that the liver is a viscoelastic 
tissue with increasing liver stiffness during the development of fibrosis. 
Hepatic stellate cells which are also anchorage-dependent cells, will sense the mechanics of 
their surroundings by pushing and pulling on the ECM, and will therefore change 
intracellular signals and cellular behaviour (Figure 1) [44, 73, 74]. Hence, investigating the 
mechanotransduction phenomenon and its effect on the HSCs phenotype has led to the 
observations that depending on the hardness of the substrates used i.e. soft versuss stiff, the 
quiescent phenotype of HSCs will be maintained or they will transform into activated 
myofibroblasts. For example, mechanical stretch enhances TGF-β expression on mRNA and 
protein levels in HSCs [75] and induces epithelial to mesenchymal transition (EMT) [76]. Rat 
HSCs exposed to static water pressure (10 mmHg, 1 h) undergo increased proliferation and 
migration [77], whereas targeting of the mechano-sensitive nuclear factor Yes-Associated 
Protein (YAP) [78, 79] and Bromodomain-containing protein 4 (BRD4) [80, 81] reversed 
liver fibrosis [82]. These in vitro studies comparing HSCs cell behaviour under different bio-
mechanical conditions are important to understand the complexity between HSCs and their 
liver ECM microenvironment in healthy liver versus diseased liver [83]. Although all 
observations made in 2D single culture, whether on plastic culture dishes or ECM matrix 
components, these in vitro models are still limited. If stiffness is affecting cell behaviour than 
the mechanical heterogeneity, which is typically found in healthy and diseased liver, is absent 
in the 2D culture models. Indeed, Desai et al. demonstrated that healthy livers are 
mechanically heterogeneous with portal tracts being stiffer than the pericentral regions, which 
suggest that cells in distinct regions of the liver can be exposed to mechanically distinct 
microenvironments [84]. Therefore, culturing HSCs on collagen in 2D does not recapitulate 
the cellular and genetic behaviour of the HSCs present in a healthy liver or the fibrous 
septa/liver nodules during the process of progressive liver fibrosis. As a consequence, 
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reductionist 2D monolayer cell culture systems with collagen or ECM substrates do not 
address fully the complex multicellular processes that give shape to the healthy or fibrotic 
liver tissue. Thus, one of the major drawbacks of using traditional 2D cultures to model living 
systems is inaccurately reflecting the physiological manner in which modulators, nutrients, 
oxygen, and metabolites are applied and removed. 
3. Translational medicine and drug discovery: how to proceed  
Over the past few decades, the invention of new efficient drugs for the treatment of liver 
disease has been hampered by the lack of robust and biologically relevant hepatic models, 
where functional pharmacokinetics and toxicological studies can be investigated [85-87]. For 
example, limitations of these in vitro culture systems are related to a fast decline in 
hepatocyte-specific functions, dedifferentiation and loss of hepatocyte polarity after short 
term culture [88, 89]. Furthermore, no efficient anti-fibrogenic therapy has been developed 
yet. Possible anti-fibrogenic effects of compounds were tested in 2D models and further 
extrapolated into in vivo models [10, 90, 91]. In many cases, drug candidates that showed 
efficacy when tested in different 2D in vitro systems did not reproduce similar successful 
effectiveness in vivo animal models, leading to misinterpretation of the data [92-94]. For 
many years, animal models have played an essential role in the process of developing drug 
compounds. This is because animal models combine the native ECM microenvironment, 
different cell types, as well as oxygen and nutritional flows [95, 96]. Limitations of using 
animal models are numerous; such as the non-human origin, significant differences in 
metabolic capacities, cytochrome P450 isoforms activity, interspecies physiologies, drug 
bioavailability and half-life, and disease adaptive mechanisms [97-100]. Many of these 
compounds fail due to undesirable toxicity and/or lack of clinical effectiveness, which is 
usually observed during the most expensive phase of clinical development i.e. phase III [86, 
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94]. Indeed, a staggering 9 out of 10 drugs that passed animal trials ended up failing human 
clinical trials [100-105]. To reduce the overall cost of liver disease drug development, 
ineffective or very toxic compounds/molecules should be excluded as soon as possible, 
preferably before animal testing takes place. Any valid system for drug testing implicates the 
consideration of both toxicity and efficacy, which in most cases are organ/tissue and cell-
specific. Therefore, in vitro tissue-specific models are necessary for the accurate prediction of 
the safety and functional drug dosage which would be suitable for High Throughput 
Screening [106-108]. One obvious solution would be using 3 dimensional models which can 
represent human tissue as much as possible by improving the structural support for cells, 
contributing to the mechanical properties of the tissue (rigidity / stiffness) and providing a 
flexible physical environment to allow remodelling in response to tissue dynamic processes 
such as wound healing. The only 3D model that would reflect the many aspects of the hepatic 
ECM is the liver ECM itself (Figure 2) as besides the aforementioned need for a 3D 
environment the ECM of the liver is known to provide bioactive cues for the cells to respond 
to the microenvironment as well as acting as a reservoir for growth factors which locally 
potentiates the cellular actions. 
 
 
4. In vitro 3D culture systems 
It is becoming clear that creating the liver microenvironment with its cell-matrix interactions, 
cell-cell adhesion and cellular signalling is difficult but is essential for liver studies. As 
mentioned before, traditional 2D cell culture systems have proven to be valid in investigating 
possible mechanisms of cell behaviour and for drug screening but have limitations in 
maintaining cell behaviour as observed in a 3D microenvironment (Table 1). Henceforth, 
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efforts have been made to develop well-defined 3D in vitro models which mimic ECM 
structures as found in vivo. These studies could provide several benefits such as simulating 
the liver physiology under an in vivo-like microenvironment thus enhancing liver 
functionality, constructing complex microscale ultra-structures which are the most critical 
criterion in liver tissue engineering. This can provide a rapid, easy and high-throughput 
screening process using a small number of human cells. Moreover, a critical factor for 
promoting liver cell-specific functions in vitro is the co-culturing of hepatocytes with non-
parenchymal cells either in direct contact or via paracrine stimulation in these newly 
developed in vitro systems [49, 109]. 
 
4.1.  3D cell-cell interactions and co-culture systems 
Differentiation, migration and proliferation are key cellular functions strongly regulated by 
signals from other cells [110]. Therefore, an ideal in vitro model needs to resemble tissue 
specific cell-cell interactions to improve drug screening outcomes. Three dimensional culture 
systems enable the establishment of platforms in which cell-cell interactions can be fully 
investigated within the 3D microenvironment [109, 111]. The morphology and spatial 
organization maintained within 3D culture systems allow for preservation of natural adhesion 
between cells as this process is primarily mediated by cadherin proteins. Besides their 
organizational role, cadherins transduce mechanical signals within the cells which in turn 
regulate gene expression signalling pathways [112]. Therefore, key signalling pathways are 
maintained in 3D cultures and better resemble the in vivo scenario when compared to 2D 
systems. For example, the nuclear factor YAP has shown to be a critical driver of HSCs 
activation and screening for YAP inhibitors in 3D spheroids could present a novel approach 
for the treatment of liver fibrosis [79]. Furthermore, cellular heterogeneity is an essential 
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feature of all tissues and therefore it is crucial to recapitulate the interactions between 
different cell types in order to reproduce the in vivo complexity thus enabling a full 
assessment of key molecular pathways in vitro [113, 114]. In fact, several studies have 
demonstrated a superior correlation in in vivo cellular phenotype by employing co-cultures 
rather than monoculture systems. For instance, experiments employing 3D cultures with 
hepatocytes have demonstrated that 3D co-cultures of hepatocytes with HSCs favours several 
hepatocyte functions such as engraftment, proliferation and differentiation due to the 
secretion of soluble factors produced by HSCs [115-117]. Moreover, studies have shown that 
the ECM-producing stromal cells in primary liver cancer have a dynamic and flexible 
function in tumour development, which in turn can regulate the response of cancer cells to 
chemotherapy. High collagen content is a key barrier for interstitial drug penetration among 
ECM-related proteins and thereby reduces the efficacy of chemotherapeutics. Thus major 
efforts have been made using, for example, co-cultures of HSCs and hepatocytes/HCC cell 
lines in multicellular tumour spheroid models to investigate the complex signalling cascade 
between different cell types during liver diseases [118-122]. Furthermore, by using hepatic 
organoids it was shown that the fast and spontaneous activation of HSCs, as observed in 2D 
cultures on plastic, was prevented as a quiescent-like phenotype was maintained for 21 days 
in culture. In addition, HSCs retained their capacity to respond to pro-fibrotic compounds 
directly and in a hepatocyte-dependent manner [123]. 
 
4.2. Cell-ECM interactions in 3D models 
The interaction between ECM proteins and cellular receptors affect different physiological 
and pathological processes [124, 125]. These interactions lead to a series of chemical and 
mechanical stimuli which may affect the phenotype and function of both the ECM and cells 
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[126, 127]. Therefore, recreating tissue-specific human ECM, both composition and 
architecture, represents an area of research actively pursued in medicine and biology for 
improving the quality and validity of data generated from in vitro cultures. For example, 
integrins act as transmembrane receptors that play a key role in mediating the interactions 
between cells and the ECM. To do so, integrins physically connect ECM receptors with cell 
membranes and the nucleus through a cascade of signalling pathways, thus regulating cellular 
mechanisms in response to environmental stimuli [128] by affecting various cellular 
functions [129]. Moreover, integrins are able to sense changes in ECM biomechanical 
properties during liver fibrosis/cirrhosis and cancer development [83, 130-132], which may 
affect integrin-dependent signalling pathways [133]. This has been demonstrated by 
emphasizing the significant differences in signalling pathways in cells cultured on 2D and in 
3D models leading to different cell response after drug treatments [126, 134-136]. 
4.3. Tissue architecture and oxygenation in 3D models 
Tissue architecture and topography have been shown to orchestrate many cellular functions 
such as cell morphology, differentiation, polarization and gene expression [73, 84, 137]. 
Therefore, the development of 3D culture models needs to mimic the spatial organizational 
complexity of human tissues. This requests resembling the cellular interaction with ECM 
proteins, which is mediated through the binding of both apical and basal membranes with 
layers of the structural ECM proteins. Unfortunately, these bi-directional interactions are 
absent or disrupted in many 2D models [108]. Oxygenation or gradients in oxygenation are 
key for appropriate cell behaviour and are neither achievable nor considered in 2D culture 
systems. The only way of achieving or investigating the effect of oxygenation is by analysing 
the effect of hypoxia which is a key regulator in the activation of HSCs and is accomplished 
by growing cells in strictly controlled hypoxic conditions (3% O2) [18, 138, 139]. Therefore, 
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it is critical in the design of 3D in vitro platforms to mimic the tissue-specific oxygen and 
nutrient gradients in order to satisfy the tissue-specific metabolic request. In recreating the 
optimal oxygen gradient characteristically present in biological tissue it is important to 
consider that the maximum distance between a cell and a vessel is between 150 and 200 μm 
in vivo [140, 141]. Lack of regulation in oxygen levels will lead to alterations in key cellular 
functions such as cell proliferation and metabolism [142]. Regulation of oxygenation can be 
achieved by using perfused 3D models, “microphysiological systems” or “organs on chips”. 
These systems use microfluidic or microscale reactors to control the flow of culture medium. 
For example the LiverChip comprises a scaffold that fosters formation of an array of ∼0.2-
mm 3D-tissue structure with primary human hepatocytes, HSCs and Kupffer cells, and an on-
board microfluidic pumping system. Each well/scaffold is individually perfused and the 
constant recirculation maintains/enhances cell viability, cellular function and ensures 
adequate oxygenation. Thus, this dynamic system precisely perfuses the scaffold with culture 
medium to control oxygenation and shear stress on the tissue, enabling long-term culture with 
retention of physiological responses [143-145]. These perfused systems, are often better 
characterized and controllable than static cultures concerning the direct surrounding of tissues 
thus introducing well-characterized medium flow rates around the tissues allow the cell 
secretions to mix with the rich medium through perfusion. Moreover, new developments in 
multi-organ chip (MOC)-based systems combine the benefits of a controlled medium flow 
around the different engineered tissues with interconnections to demonstrate cross talk 
between the organs creating a "human-on-a-chip," a whole body biomimetic device. These 
clusters of assembled cells mimic how organs in the body function, both separately and in 
tandem. 
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4.4. 3D in vitro hepatic systems 
Advanced 3D liver models have been established by employing cell spheroids, cell sheets or 
scaffold-based 3D-cultures aimed at recreating the physiological and pathological hepatic 
microenvironment [146]. Given the structural diversity of the extracellular environment in 
vivo i.e. healthy liver versus diseased liver, it is not surprising that research towards a more in 
vivo-like system is wanted [147, 148]. Thus, major efforts have been made to mimic the in 
vivo HSCs-hepatic cell and HSCs-ECM interactions. Indeed, it has been demonstrated that 
the behaviour of HSCs is regulated by a 3D ECM [149-152]. Freshly isolated HSCs showed 
changes in cell morphology and cellular functions when comparisons were made between 2D 
plastic cultures and culturing cells in thick matrigel, 3D type I collagen gel or other substrates 
[4, 151]. Henceforth, many different approaches have provided valid information concerning 
the co-culture of parenchymal cells with HSCs. For example the paracrine effect of rat HSCs 
on primary hepatocytes was investigated by using a spheroid-based 3D culture. A chip was 
created with a “cascade” design in which the HSCs culture medium flowed towards the 
hepatocytes cultured in 3D-spheroids. This enabled the separate investigation of HSCs and 
hepatocyte specific functions over a short period of time [109]. The 3D-Spheroids system 
also allows the development of 3D hepatocyte cultures and in fact was one of the first models 
developed [153]. The hepatocytes grown in 3D spheroids form multicellular clusters that 
produce ECM allowing for cell-ECM and cell-cell interactions [154, 155]. This has proven to 
preserve hepatic-specific functions and differentiation when compared with 2D culture 
systems [156]. Thus the 3D spheroids allow the study of drug pharmacokinetics and toxicity 
in order to identify the most appropriate dose [157]. Limitations of this system include the 
variability of the spheroid size i.e. data reproducibility during drug efficacy and toxicity 
studies and assembly time of the 3D spheroids [154]. In contrast, by using micromold-based 
procedures, uniform microsized spheroids can be produced and are typically small enough 
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(<100 μm diameter) to ensure good diffusion of oxygen and nutrients. These spheroids can 
also be used as building blocks to create larger organoids [158]. Another system takes the 
advantage of inoculating primary hepatocytes into a pre-established non-parenchymal cell 
culture grown on 3D nylon scaffolds. This approach allows a culturing time for up to 3 
months while maintaining important hepatic functions [49]. Furthermore, the Scar-in-a-Jar 
3D model is based on culturing fibroblasts with addition of neutral or charged 
macromolecules [159] that may provide a new pathophysiological relevant in vitro screening 
assay. This system analyses antifibrotic lead compounds which specifically target the 
collagen biosynthesis. This system favours collagen protein synthesis and secretion when 
compared to traditional 2D plastic culture dishes [160]. Although, whether the profibrogenic 
cell behaviour of the HSCs and more specifically the screening of antifibrogenic compounds 
will render this system favourable has yet to be proven. All systems described contain several 
limitations such as the presence of a standardised matrix stiffness and a uniform topography 
[161, 162] which are likely two major variables that greatly contribute to an altered HSCs 
phenotype in different liver diseases, thereby changing HSCs cell behaviour.  
4.5.  Precision cut liver slices  
Precision-Cut Liver Slices (PCLS) is a 3D in vitro model to study HSCs in a system that 
closely reflects the in vivo situation with maintaining the intact hepatic architecture and 
cellular heterogeneity [161]. This 3D system can be obtained from different species such as 
rat [163], mouse [164] and human liver [165, 166] [167, 168]. The liver slices are 8 mm in 
diameter, 250 μm thick and contain 70 to 100 lobules. They are maintained in a vial that is set 
on a roller platform and gently agitated at 37 degrees Celsius, with 5% CO2 and 40% O2 in a 
humidified incubator. This set up allows performing experiments over a time period of 24 
hours to 1 week [169-171], although, this short incubation time might be considered a major 
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drawback of this system. Furthermore, proteomics analysis has shown to give different 
outcomes depending on the species investigated [164, 166]. On the other hand, by using this 
3D in vitro model the cellular behaviour of hepatocytes and all non-parenchymal cells in the 
native ECM microenvironment can be investigated [168, 172].  
 
4.6.  Cell sheet stacking 
Cell sheet engineering is a unique scaffold-free tissue-engineering approach that uses poly(N-
isopropylacrylamide) (PNIPAAm)-grafted, temperature-responsive culture dishes (TRCDs). 
The temperature-responsive culture surface can be developed by implanting a temperature-
responsive PIPAAm gel into a standard tissue culture polystyrene dish. This material 
alternates between hydrophobicity and hydrophilicity based on the working temperatures, 
which further affects the capability of the cells to attach to the material. Indeed, at low 
temperature (20°C) the surface of the material becomes hydrophilic and cells cannot attach. 
In contrast, at 37°C the shell turns hydrophobic and cells can attach and proliferate on the 
surface. Thus, cells expanded on the surface can be harvested without enzymatic treatment 
(e.g trypsin) but simply by reducing the temperature. Interestingly, the interaction between 
cells remained preserved and several layers of cell sheets can be assembled together in order 
to build more complex 3D structures [173, 174]. Notably, hepatic cell sheets have been 
produced by using both parenchymal and non-parenchymal cells and this system enhanced 
hepatic functions such as albumin and urea synthesis compared to 2D monolayer cultures 
[146, 175]. Nevertheless, due to absence of vascularisation and therefore oxygen supply, the 
hepatocyte cell sheet system can only be used for a short period of time because of the 
consequent ischemic process. In contrast, similar cell sheet models containing cord blood-
derived endothelial colony-forming cells (ECFCs), sandwiched with fibroblasts sheets, 
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recreated prevascularised 3D cell-dense tissue constructs and formed functional microvessels 
after 1 week of transplantation in vivo [173]. 
4.7. Scaffold/matrix-based 3D cultures 
One of the most exploited systems for the development of 3D in vitro culture platform 
consists of reseeded cells in 3D scaffolds. These scaffolds can be made of synthetic or 
derived from biological sources. Synthetic scaffolds can easily be manufactured but lack key 
features such as physiological bioactivity, biomechanics and accurate microarchitecture. The 
most common artificial matrices employed for engineering biological tissue are synthetic 
polymers (e.g. polylactide-co-glycolide (PLG), Polyethylene glycol (PEG)), polycaprolactone 
(PLA) [176] [177] and naturally-derived hydrogels (e.g., alginates, celluloses, polyethylene) 
[178], respectively [179-181]. 
In addition, 3D scaffolds can be developed from biological ECM-derived material. For 
instance, several substrates have employed basement membrane or type I collagen gels. 
These materials are characterized by the preservation of ECM molecules that improve cell 
attachment and differentiation. Several limitations mark these biological gels, as it is difficult 
to obtain batches of gels marked by homogenous mechanical properties [179, 180] and these 
gels do not resemble natural 3D tissue-microarchitecture. Therefore cells encapsulated in 
these gels randomly self-organize into a non-physiological 3D structure. Moreover, these 
materials are often not tissue-specific thereby affecting the reproduction and maintenance of 
specific liver metabolic function [181]. To overcome this limitation, the development of 
human ECM hydrogel with retained ECM protein composition using lyophilized 
decellularized tissue should provide the most optimal physiological microenvironment for 
cell culture in order to promote survival and proliferation of hepatic cells [182].    
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4.8.  Decellularised 3D scaffolds 
Over the past few decades, several studies have demonstrated the suitability of using 
decellularized human or animal tissue by employing naturally occurring ECM scaffolds for 
tissue engineering [183-188]. In this context, liver bioengineering has the potential to be 
utilised for transplantation and as 3D in vitro cultures for toxicity testing during preclinical 
drug development. There is indeed convincing experimental evidence that “Decellularisation-
Recellularisation” technologies provide a valuable platform for liver bioengineering through 
the repopulation of a liver ECM scaffold with appropriate parenchymal and non-parenchymal 
liver cells [189, 190]. Moreover, decellularisation protocols need to be tissue-specific due to 
the high variability of ECM protein compositions between different types of tissue [191], as 
well as disease-specific [190, 192, 193] and species-specific, in order to recapitulate the 
human pathophysiological 3D environment. Some limitations with other 3D platforms have 
been overcome by using decellularised hepatic tissue. Hepatic function of primary HSCs has 
been maintained in vitro for 3 weeks. Additionally, preservation of the vessels within the 
decellularised hepatic tissue has been achieved, including re-endothelialisation of the vessels 
with human umbilical vein endothelial cells (HUVECs) in vitro and neoangiogenesis in vivo 
[194, 195]. Furthermore, Yang et al. have demonstrated the preservation of bioactive factors, 
such as bFGF, PDGF and VEGF, within the decellularised tissue [196]. However, limitations 
of decellularised tissue scaffolds include availability of healthy human liver tissue and access 
to diseased liver tissue. 
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Conclusions 
Despite all the major improvements in refining the isolation methods and culture conditions 
in 2D and 3D, there is no efficient antifibrogenic therapy available [10, 90]. Many promising 
compounds fail when translated from 2D in vitro cultures to in vivo models owing to the lack 
of liver specific microenvironment. The absence of physiological, routine and easy to 
perform 3D in vitro screening assays slowdown or halt further investigation of possible lead 
compounds before they can be tested in animal models or commencement of phase I clinical 
trials. Overall, the optimization of these in vitro models will lead to new objectives and to a 
possible new era in the search for antifibrogenic compounds.  
Furthermore improvements in in vitro culture models which more closely reflect the liver 
microenvironment need to be investigated. Therefore research efforts continue to optimize 
3D biosystems composed of single and/or co-culture platforms. In this aspect, HSCs showed 
to be very important as secondary supportive or stromal cells to obtain a heterotypic 
interaction between the parenchymal cells. Indeed, non-parenchymal cells such as HSCs 
increase the viability and functionality of hepatocytes in the 3D biosystems, made of 
synthetic and biological-derived materials [117, 197, 198]. Finally, it will be paramount to 
design a routine 3D cell culture system for researchers in both academia and the 
pharmaceutical industry. 
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Figure Legends 
Figure 1. Key differences in 2D and 3D support systems which affect HSCs behaviour and 
therefore drug screening. Culturing HSCs on 2D plastic culture dishes deprived of important 
ECM-specific bioactive cues, with a stiffness of more than 2GPa, has a major impact on cell 
morphology with cell-cell interactions only on the x-y plane. When HSCs are grown on a 
hand-made scaffold stiffness can be chosen (1 – 20 kPa). In this 3D microenvironment the 
HSCs cell body is in contact with the surrounding 3D microenvironment and cell-cell 
interactions are present on all planes.  
Figure 2. Schematic overview of different systems, with advantages and disadvantages, for 
culturing HSCs in vitro. Growing freshly isolated HSCs obtained from a healthy liver in 2D 
cell cultures allows to study the HSCs transdifferentiation into in vitro activated HSC. 
Culturing HSCs in 3D cultures favours the study of HSCs cell behaviour in the 3 dimensional 
microenvironment and the interaction with other hepatic cells. Precision-Cut Liver Slices is a 
3D in vitro model to study HSCs in a system that closely reflects the in vivo situation with 
maintaining the intact hepatic architecture and cellular heterogeneity. Repopulation of HSCs 
in 3D human liver acellular scaffolds favours the study of HSCs biology as the scaffolds 
maintains the ECM protein composition, 3D-architecture and physicochemical properties of 
the native tissue. 
Table 1. Comparison of limitations and strengths of classical cell culture techniques with 
recently developed 3D culture systems specific for modelling diseases in which tissue 
remodelling is a key factor in disease progression such as for example fibrosis and cancer. 
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